Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/12535
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Coquet, Jonathan M | en |
dc.contributor.author | Skak, Kresten | en |
dc.contributor.author | Davis, Ian D | en |
dc.contributor.author | Smyth, Mark J | en |
dc.contributor.author | Godfrey, Dale I | en |
dc.date.accessioned | 2015-05-16T02:14:41Z | |
dc.date.available | 2015-05-16T02:14:41Z | |
dc.date.issued | 2013-10-18 | en |
dc.identifier.citation | Clinical & Translational Immunology 2013; 2(10): e6 | en |
dc.identifier.govdoc | 25505948 | en |
dc.identifier.other | PUBMED | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/12535 | en |
dc.description.abstract | Interleukin-21 (IL-21) is a common γ-chain cytokine produced by T helper and natural killer T (NKT) cells. It has been shown to regulate the response of various lymphocyte subsets including NK, NKT, T and B cells. Owing to its potent anti-tumor function in preclinical studies and its ability to induce cytotoxicity and interferon-γ (IFN-γ) production in NK and CD8 T cells, recombinant IL-21 (rIL-21) was fast-tracked into early-phase clinical trials of patients with various malignancies. In a phase 2a trial of patients with metastatic melanoma, we analyzed the frequency and function of NKT cells in patients receiving rIL-21. NKT cells were present at a low frequency, but their levels were relatively stable in patients administered rIL-21. Unlike our observations in NK and CD8 T cells, rIL-21 appeared to reduce IFN-γ and TNF production by NKT cells, whereas it enhanced IL-4 production. It also modulated the expression of cell surface markers, specifically on CD4(-) NKT cells. In addition, an increase in CD3(+)CD56(+) NKT-like cells was observed over the course of rIL-21 administration. These results highlight that IL-21 is a potent regulator of NKT cell function in vivo. | en |
dc.language.iso | en | en |
dc.subject.other | Cancer | en |
dc.subject.other | IL-21 | en |
dc.subject.other | NKT | en |
dc.subject.other | T helper | en |
dc.title | IL-21 Modulates Activation of NKT Cells in Patients with Stage IV Malignant Melanoma. | en |
dc.type | Journal Article | en |
dc.identifier.journaltitle | Clinical & translational immunology | en |
dc.identifier.affiliation | Cancer Immunology Program, Peter MacCallum Cancer Centre , East Melbourne, Victoria, Australia ; Immunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research , Herston, Queensland, Australia ; School of Medicine, University of Queensland , Herston, Queensland, Australia | en |
dc.identifier.affiliation | Department of Microbiology and Immunology, University of Melbourne , Parkville, Victoria, Australia | en |
dc.identifier.affiliation | Ludwig Institute for Cancer Research, Austin Health , Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Department of Histology and Cancer Pharmacology, Novo Nordisk A/S , Maalov, Denmark. | en |
dc.identifier.doi | 10.1038/cti.2013.7 | en |
dc.description.pages | e6 | en |
dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/25505948 | en |
dc.type.austin | Journal Article | en |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.